Last reviewed · How we verify
Placebo (for Dabigatran)
Placebo does not have a pharmacological effect.
Placebo does not have a pharmacological effect. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Placebo (for Dabigatran) |
|---|---|
| Sponsor | Population Health Research Institute |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
A placebo is a dummy treatment that has no therapeutic effect. It is used as a control in clinical trials to compare the efficacy of active treatments.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Injection site reaction
Key clinical trials
- Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers (PHASE1)
- VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI) (PHASE1)
- A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age. (PHASE1)
- Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation (EARLY_PHASE1)
- Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation (PHASE4)
- Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis (NA)
- Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) (PHASE3)
- Management of Myocardial Injury After Noncardiac Surgery Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for Dabigatran) CI brief — competitive landscape report
- Placebo (for Dabigatran) updates RSS · CI watch RSS
- Population Health Research Institute portfolio CI